Biogen Inc [BIIB] stock prices are up 2.35% to $186.91 at the moment. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling. The BIIB shares have gain 5.96% over the last week, with a monthly amount glided 3.09%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Previously, HSBC Securities downgraded its rating to Reduce on December 10, 2025, and kept the price target unchanged to $143. On November 06, 2025, upgrade upgraded it’s rating to Buy but maintained its price target of $202 on the stock. Jefferies started tracking the stock assigning a Buy rating and suggested a price target of $190 on September 25, 2025. HSBC Securities downgraded its rating to Hold for this stock on April 28, 2025, but kept the price target unchanged to $118. In a note dated April 04, 2025, Argus downgraded a Hold rating on this stock.
The stock price of Biogen Inc [BIIB] has been fluctuating between $110.04 and $185.17 over the past year. Currently, Wall Street analysts expect the stock to reach $174.38 within the next 12 months. Biogen Inc [NASDAQ: BIIB] shares were valued at $186.91 at the most recent close of the market. An investor can expect a potential drop of -6.7% based on the average BIIB price forecast.
Analyzing the BIIB fundamentals
The Biogen Inc [NASDAQ:BIIB] reported sales of 9.69B for trailing twelve months, representing a surge of 3.33%. Gross Profit Margin for this corporation currently stands at 0.72% with Operating Profit Margin at 0.24%, Pretax Profit Margin comes in at 0.19%, and Net Profit Margin reading is 0.16%. To continue investigating profitability, this company’s Return on Assets is posted at 0.06, Equity is 0.09 and Total Capital is 0.09. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.36.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 183.39 points at the first support level, and at 179.86 for the second support level. However, for the 1st resistance point, the stock is sitting at 188.75, and for the 2nd resistance point, it is at 190.58.
Ratios To Look Out For
It’s worth pointing out that Biogen Inc [NASDAQ:BIIB]’s Current Ratio is 2.72. In addition, the Quick Ratio stands at 2.04 and the Cash Ratio stands at 1.17. Considering the valuation of this stock, the price to sales ratio is 2.83, the price to book ratio is 1.51 and price to earnings (TTM) ratio is 17.05.
Transactions by insiders
Recent insider trading involved Singhal Priya, Head of Development, that happened on Sep 02 ’25 when 517.0 shares were sold. Officer, Singhal Priya completed a deal on Sep 02 ’25 to buy 517.0 shares. Meanwhile, Head of Global Product Strat. Izzar Rachid sold 2223.0 shares on Jul 08 ’25.
